ArticleDiabetes, obesity & metabolism2022

Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.

William H Polonsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.